Xenetic Biosciences Inc (XBIO) Receives Average Recommendation of “Strong Buy” from Brokerages

Xenetic Biosciences Inc (NASDAQ:XBIO) has received an average broker rating score of 1.00 (Strong Buy) from the one analysts that cover the stock, Zacks Investment Research reports.

Zacks has also given Xenetic Biosciences an industry rank of 154 out of 265 based on the ratings given to its competitors.

Separately, Zacks Investment Research raised shares of Xenetic Biosciences from a “hold” rating to a “buy” rating and set a $3.00 price target for the company in a report on Saturday, September 16th.

Xenetic Biosciences (XBIO) opened at $2.09 on Tuesday. Xenetic Biosciences has a 12 month low of $1.75 and a 12 month high of $5.90. The stock has a market cap of $17.96, a price-to-earnings ratio of -1.69 and a beta of 2.19.

Xenetic Biosciences (NASDAQ:XBIO) last issued its quarterly earnings results on Wednesday, November 15th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.03). The company had revenue of $0.09 million during the quarter. Xenetic Biosciences had a negative return on equity of 85.94% and a negative net margin of 2,654.00%.

ILLEGAL ACTIVITY WARNING: “Xenetic Biosciences Inc (XBIO) Receives Average Recommendation of “Strong Buy” from Brokerages” was first published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this story on another publication, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be viewed at https://www.com-unik.info/2018/01/09/xenetic-biosciences-inc-xbio-receives-average-recommendation-of-strong-buy-from-brokerages.html.

About Xenetic Biosciences

Xenetic Biosciences, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the research and development of certain pharmaceutical products for use in humans that includes the use of the Company’s platform technologies that enables the creation of drug therapies primarily for orphan indications.

Get a free copy of the Zacks research report on Xenetic Biosciences (XBIO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Xenetic Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenetic Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit